Montanide ISA 51(Roswell Park Cancer Institute)

N/A

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug NameMontanide ISA 51(Roswell Park Cancer Institute)
Drug Alias NameIncomplete Freund''s Adjuvant(Roswell Park Cancer Institute)
ClassificationOther
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsNeuroendocrine Carcinoma of LungSolid tumoursNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRoswell Park Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer Institute
Inactive CompaniesN/A
Active IndicationsNeuroendocrine Carcinoma of LungSolid tumoursNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A